Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Prevent Avigan Use in Potentially Pregnant COVID-19 Patients: Minister
September 21, 2021
- Chuikyo Raises No Objections to MHLW Proposal on Revision of CEA Analysis Process
September 17, 2021
- Japan to Start Pilot Project for Home Use of Antibody Cocktail: Minister
September 17, 2021
- Daiichi Sankyo Missed Goal on CEA Data Submission, but Delay Deemed Reasonable
September 16, 2021
- DPO Minutes to Be Disclosed 2 Months after Chuikyo General Assembly
September 16, 2021
- Tainted Moderna Jabs Run Afoul of PMD Law: Minister
September 16, 2021
- Kazuhito Ihara to Helm Health Policy Bureau; Vice Minister Tarumi to Stay
September 15, 2021
- Japan Eyes Legal System to Ensure Generic Supplies in New Industry Vision, Key Official Says It’s Difficult with Companies’ Own Efforts Alone
September 15, 2021
- MHLW Unapproved Drug Panel Agrees on High Needs for 7 Additional Indications for Fertility Treatments
September 14, 2021
- 16,680 Doses Ruined in Workplace Inoculations; Bayer, Otsuka Too
September 14, 2021
- COVID-19 Jabs Need 3 Month Interval after Antibody Cocktail Use: MHLW
September 14, 2021
- Panel OKs 37 More COVID-19 Jab Health Damage Claims for Compensation
September 14, 2021
- Japan Unveils New Pharma Industry Vision, 1st Update in 8 Years
September 14, 2021
- SaMD Would Be Evaluated Like Ordinary Medical Devices: PMDA Official
September 13, 2021
- PMDA Reviewing Safety Risks for Ivermectin, Xeljanz
September 13, 2021
- Causal Link between Deaths and Recalled Batch of Moderna Jab “Indeterminable”
September 13, 2021
- MHLW to Promptly Seek Expert Panel Discussion on Booster Shots: Minister
September 13, 2021
- Japan Should Arrange Boosters Immediately, Mix-and-Match Doses Too: LDP
September 10, 2021
- Regional Governors Club Urges Early Conclusion on HPV Vaccines
September 10, 2021
- COVID-19 Antibody Cocktail Given to 13,000 in Japan by August-End: MHLW
September 10, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…